Affimed presents positive data for AFM24 plus Atezolizumab in NSCLC patients

From GlobeNewswire: 2024-06-01 13:02:00

Affimed N.V. announced data from the AFM24-102 trial showing that in EGFRwt NSCLC patients, AFM24 plus atezolizumab achieved 4 objective responses with 3 ongoing for more than 7 months. The combination therapy also demonstrated responses in EGFRmut NSCLC patients, confirming activity. The company reported a manageable safety profile. A conference call/webcast to discuss the updated data will be held today at 6:00 p.m. CDT / 7:00 p.m. EDT. This trial aims to address unmet medical needs in refractory NSCLC patients by combining AFM24 with PD-1/PD-L1 blockade. Further updates are expected in the second half of 2024.



Read more at GlobeNewswire: Affimed Provides Follow-up Data of AFM24 plus Atezolizumab